In July 2023, Eli Lilly made a nearly $2 billion bet on Versanis' ActRII inhibitor, Bimagrumab, citing its ability to...

Since December 2023, there have been several positive updates about drugs targeting MSLN. On December 19th, RemeGen announced that the...

Colorectal cancer (CRC) is recognized as one of the most common and life-threatening malignancies, with an increasing proportion of advanced...

Neuroendocrine neoplasms/tumors (NENs or NETs) are rare tumors that originate from specialized cells called neuroendocrine cells. These cells have characteristics...

Immunotherapy is an essential option for current disease treatment. However, most patients fail to respond adequately to existing immunotherapies, such...

On November 13, 2023, Legend Biotech officially announced that its wholly-owned subsidiary, Legend Biotech Ireland Limited, has entered into an...

Every year, on August 18th, the world comes together to observe World Breast Cancer Research Day—a day dedicated to raising...

MICA, also known as MHC Class I Polypeptide-Related Sequence A, is a type I MHC molecule that is highly homologous...

Organoids are a three-dimensional model established in vitro that is highly similar to tissues or organs in vivo, and can...

At the ASCO annual meeting in 2023, Boehringer-Ingelheim disclosed the phase I clinical data of their bispecific antibody drug BI...

Colorectal cancer (CRC) is the third most common tumor and the most common tumor of the digestive system. With the...

The process of tumor cell infiltration, adhesion and migration is an important research direction in the process of drug development....